CD8A and cancer: The combination of protein-based cancer vaccine with oncolytic virus in heterologous prime-boost setting has been previously shown to elicit a robust and durable antigen-specific CD8 T cell response associated with a profound remodeling of the tumor microenvironment, resulting in strong tumor growth inhibition in mouse models [7,8].